KESTRA MED TECHNOLOGIES LTD Financials
This page shows KESTRA MED TECHNOLOGIES LTD (KMTS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 2 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores
KESTRA MED TECHNOLOGIES LTD has an operating margin of -177.8%, meaning the company retains $-178 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -305.8% the prior year.
KESTRA MED TECHNOLOGIES LTD's revenue surged 115.1% year-over-year to $59.8M, reflecting rapid business expansion. This strong growth earns a score of 100/100.
KESTRA MED TECHNOLOGIES LTD carries a low D/E ratio of 0.23, meaning only $0.23 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 6.84, KESTRA MED TECHNOLOGIES LTD holds $6.84 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
While KESTRA MED TECHNOLOGIES LTD generated -$77.6M in operating cash flow, capex of $22.9M consumed most of it, leaving -$100.5M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
KESTRA MED TECHNOLOGIES LTD passes 5 of 9 financial strength tests. 2 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
For every $1 of reported earnings, KESTRA MED TECHNOLOGIES LTD generates $0.68 in operating cash flow (-$77.6M OCF vs -$113.8M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
KESTRA MED TECHNOLOGIES LTD earns $-13.8 in operating income for every $1 of interest expense (-$106.4M vs $7.7M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
KESTRA MED TECHNOLOGIES LTD generated $59.8M in revenue in fiscal year 2025. This represents an increase of 115.1% from the prior year.
KESTRA MED TECHNOLOGIES LTD's EBITDA was -$98.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 33.9% from the prior year.
KESTRA MED TECHNOLOGIES LTD generated -$100.5M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 19.0% from the prior year.
KESTRA MED TECHNOLOGIES LTD reported -$113.8M in net income in fiscal year 2025. This represents a decrease of 20.9% from the prior year.
KESTRA MED TECHNOLOGIES LTD earned $-5.13 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 1.2% from the prior year.
KESTRA MED TECHNOLOGIES LTD held $201.2M in cash against $41.5M in long-term debt as of fiscal year 2025.
KESTRA MED TECHNOLOGIES LTD had 51M shares outstanding in fiscal year 2025. This represents an increase of 48430.0% from the prior year.
KESTRA MED TECHNOLOGIES LTD's gross margin was 40.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 39.2 percentage points from the prior year.
KESTRA MED TECHNOLOGIES LTD's operating margin was -177.8% in fiscal year 2025, reflecting core business profitability. This is up 128.0 percentage points from the prior year.
KESTRA MED TECHNOLOGIES LTD's net profit margin was -190.3% in fiscal year 2025, showing the share of revenue converted to profit. This is up 148.1 percentage points from the prior year.
KESTRA MED TECHNOLOGIES LTD invested $15.7M in research and development in fiscal year 2025. This represents an increase of 1.0% from the prior year.
KESTRA MED TECHNOLOGIES LTD invested $22.9M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 87.6% from the prior year.
KMTS Income Statement
| Metric | Q2'25 | Q1'25 | Q1'24 |
|---|---|---|---|
| Revenue | $22.6M+16.5% | $19.4M | N/A |
| Cost of Revenue | $11.1M+5.9% | $10.5M | N/A |
| Gross Profit | $11.4M+29.1% | $8.9M | N/A |
| R&D Expenses | $4.9M+21.9% | $4.0M | N/A |
| SG&A Expenses | $38.3M+13.6% | $33.7M | N/A |
| Operating Income | -$31.8M-10.0% | -$28.9M | N/A |
| Interest Expense | $1.9M-0.6% | $1.9M | N/A |
| Income Tax | $34K+3.0% | $33K | N/A |
| Net Income | -$32.8M-26.9% | -$25.8M | N/A |
| EPS (Diluted) | $-0.64-28.0% | $-0.50 | N/A |
KMTS Balance Sheet
| Metric | Q2'25 | Q1'25 | Q1'24 |
|---|---|---|---|
| Total Assets | $246.7M-7.4% | $266.3M+479.5% | $45.9M |
| Current Assets | $195.4M-11.5% | $220.7M+1380.5% | $14.9M |
| Cash & Equivalents | $175.4M-12.8% | $201.2M+2339.3% | $8.2M |
| Inventory | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A |
| Total Liabilities | $82.6M+0.6% | $82.1M-67.8% | $255.3M |
| Current Liabilities | $35.8M+10.9% | $32.3M-2.2% | $33.0M |
| Long-Term Debt | $41.9M+0.9% | $41.5M-2.5% | $42.5M |
| Total Equity | $164.1M-10.9% | $184.2M+188.0% | -$209.4M |
| Retained Earnings | -$578.9M-6.0% | -$546.1M-34.4% | -$406.4M |
KMTS Cash Flow Statement
| Metric | Q2'25 | Q1'25 | Q1'24 |
|---|---|---|---|
| Operating Cash Flow | -$18.3M+30.2% | -$26.3M | N/A |
| Capital Expenditures | $7.3M-11.0% | $8.2M | N/A |
| Free Cash Flow | -$25.6M+25.6% | -$34.4M | N/A |
| Investing Cash Flow | -$7.4M+9.9% | -$8.2M | N/A |
| Financing Cash Flow | -$27K+98.6% | -$1.9M | N/A |
| Dividends Paid | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A |
KMTS Financial Ratios
| Metric | Q2'25 | Q1'25 | Q1'24 |
|---|---|---|---|
| Gross Margin | 50.6%+4.9pp | 45.7% | N/A |
| Operating Margin | -140.7%+8.3pp | -149.1% | N/A |
| Net Margin | -145.3%-12.0pp | -133.3% | N/A |
| Return on Equity | N/A | N/A | N/A |
| Return on Assets | -13.3%-3.6pp | -9.7% | N/A |
| Current Ratio | 5.47-1.4 | 6.84+6.4 | 0.45 |
| Debt-to-Equity | 0.26+0.0 | 0.23+0.4 | -0.20 |
| FCF Margin | -113.5%+64.3pp | -177.8% | N/A |
Similar Companies
Frequently Asked Questions
What is KESTRA MED TECHNOLOGIES LTD's annual revenue?
KESTRA MED TECHNOLOGIES LTD (KMTS) reported $59.8M in total revenue for fiscal year 2025. This represents a 115.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is KESTRA MED TECHNOLOGIES LTD's revenue growing?
KESTRA MED TECHNOLOGIES LTD (KMTS) revenue grew by 115.1% year-over-year, from $27.8M to $59.8M in fiscal year 2025.
Is KESTRA MED TECHNOLOGIES LTD profitable?
No, KESTRA MED TECHNOLOGIES LTD (KMTS) reported a net income of -$113.8M in fiscal year 2025, with a net profit margin of -190.3%.
What is KESTRA MED TECHNOLOGIES LTD's earnings per share (EPS)?
KESTRA MED TECHNOLOGIES LTD (KMTS) reported diluted earnings per share of $-5.13 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is KESTRA MED TECHNOLOGIES LTD's EBITDA?
KESTRA MED TECHNOLOGIES LTD (KMTS) had EBITDA of -$98.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does KESTRA MED TECHNOLOGIES LTD have?
As of fiscal year 2025, KESTRA MED TECHNOLOGIES LTD (KMTS) had $201.2M in cash and equivalents against $41.5M in long-term debt.
What is KESTRA MED TECHNOLOGIES LTD's gross margin?
KESTRA MED TECHNOLOGIES LTD (KMTS) had a gross margin of 40.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is KESTRA MED TECHNOLOGIES LTD's operating margin?
KESTRA MED TECHNOLOGIES LTD (KMTS) had an operating margin of -177.8% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is KESTRA MED TECHNOLOGIES LTD's net profit margin?
KESTRA MED TECHNOLOGIES LTD (KMTS) had a net profit margin of -190.3% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is KESTRA MED TECHNOLOGIES LTD's free cash flow?
KESTRA MED TECHNOLOGIES LTD (KMTS) generated -$100.5M in free cash flow during fiscal year 2025. This represents a -19.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is KESTRA MED TECHNOLOGIES LTD's operating cash flow?
KESTRA MED TECHNOLOGIES LTD (KMTS) generated -$77.6M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are KESTRA MED TECHNOLOGIES LTD's total assets?
KESTRA MED TECHNOLOGIES LTD (KMTS) had $266.3M in total assets as of fiscal year 2025, including both current and long-term assets.
What are KESTRA MED TECHNOLOGIES LTD's capital expenditures?
KESTRA MED TECHNOLOGIES LTD (KMTS) invested $22.9M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does KESTRA MED TECHNOLOGIES LTD spend on research and development?
KESTRA MED TECHNOLOGIES LTD (KMTS) invested $15.7M in research and development during fiscal year 2025.
How many shares does KESTRA MED TECHNOLOGIES LTD have outstanding?
KESTRA MED TECHNOLOGIES LTD (KMTS) had 51M shares outstanding as of fiscal year 2025.
What is KESTRA MED TECHNOLOGIES LTD's current ratio?
KESTRA MED TECHNOLOGIES LTD (KMTS) had a current ratio of 6.84 as of fiscal year 2025, which is generally considered healthy.
What is KESTRA MED TECHNOLOGIES LTD's debt-to-equity ratio?
KESTRA MED TECHNOLOGIES LTD (KMTS) had a debt-to-equity ratio of 0.23 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is KESTRA MED TECHNOLOGIES LTD's return on assets (ROA)?
KESTRA MED TECHNOLOGIES LTD (KMTS) had a return on assets of -42.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is KESTRA MED TECHNOLOGIES LTD's cash runway?
Based on fiscal year 2025 data, KESTRA MED TECHNOLOGIES LTD (KMTS) had $201.2M in cash against an annual operating cash burn of $77.6M. This gives an estimated cash runway of approximately 31 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is KESTRA MED TECHNOLOGIES LTD's Piotroski F-Score?
KESTRA MED TECHNOLOGIES LTD (KMTS) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are KESTRA MED TECHNOLOGIES LTD's earnings high quality?
KESTRA MED TECHNOLOGIES LTD (KMTS) has an earnings quality ratio of 0.68x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can KESTRA MED TECHNOLOGIES LTD cover its interest payments?
KESTRA MED TECHNOLOGIES LTD (KMTS) has an interest coverage ratio of -13.8x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is KESTRA MED TECHNOLOGIES LTD?
KESTRA MED TECHNOLOGIES LTD (KMTS) scores 60 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.